

Geremia B Bolli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9558806/publications.pdf>

Version: 2024-02-01

82
papers

4,118
citations

126708

33
h-index

114278

63
g-index

88
all docs

88
docs citations

88
times ranked

2419
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypoglycemia, Diabetes, and Cardiovascular Events. <i>Diabetes Care</i> , 2010, 33, 1389-1394.	4.3	374
2	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). <i>Diabetes Care</i> , 2014, 37, 2755-2762.	4.3	302
3	The "Dawn Phenomenon" A Common Occurrence in Both Non-Insulin-Dependent and Insulin-Dependent Diabetes Mellitus. <i>New England Journal of Medicine</i> , 1984, 310, 746-750.	13.9	230
4	Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes Mellitus. <i>New England Journal of Medicine</i> , 1985, 312, 1473-1479.	13.9	228
5	Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes. <i>Diabetes Care</i> , 2007, 30, 2447-2452.	4.3	206
6	Insulin glargine. <i>Lancet, The</i> , 2000, 356, 443-445.	6.3	190
7	Abnormal Glucose Counterregulation after Subcutaneous Insulin in Insulin-Dependent Diabetes Mellitus. <i>New England Journal of Medicine</i> , 1984, 310, 1706-1711.	13.9	184
8	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). <i>Diabetes Care</i> , 2015, 38, 2217-2225.	4.3	183
9	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. <i>Diabetes Care</i> , 2018, 41, 2147-2154.	4.3	159
10	Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at Mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. <i>Diabetes Care</i> , 2003, 26, 1490-1496.	4.3	140
11	Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime) Tj ETQq1 1 0.784314 rgBT /Overlock 32, 1170-1176.	4.3	112
12	Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2626-2630.	4.3	93
13	Glucose Counterregulation and Waning of Insulin in the Somogyi Phenomenon (Posthypoglycemic) Tj ETQq1 1 0.784314 rgBT /Overlock 13.9	13.9	87
14	Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes. <i>Diabetes Care</i> , 2013, 36, 3860-3862.	4.3	77
15	Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1986, 35, 649-656.	1.5	63
16	Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. <i>Diabetes Care</i> , 2015, 38, 2204-2210.	4.3	61
17	Insulin therapy and hypoglycaemia: the size of the problem. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, S32-S42.	1.7	60
18	Pharmacokinetics and Pharmacodynamics of Basal Insulins. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, S-15-S-24.	2.4	57

#	ARTICLE	IF	CITATIONS
19	Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Archives of Physiology and Biochemistry, 2008, 114, 3-10.	1.0	55
20	Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes. Diabetes Care, 2007, 30, 1261-1263.	4.3	52
21	Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study. Diabetes Care, 2011, 34, 1312-1314.	4.3	50
22	The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes, Obesity and Metabolism, 2020, 22, 743-754.	2.2	50
23	Administration of Neutral Protamine Hagedorn Insulin at Bedtime versus with Dinner in Type 1 Diabetes Mellitus To Avoid Nocturnal Hypoglycemia and Improve Control. Annals of Internal Medicine, 2002, 136, 504.	2.0	49
24	Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units \cdot mL ⁻¹ and Insulin Degludec 100 units \cdot mL ⁻¹ in Type 1 Diabetes. Diabetes Care, 2021, 44, 125-132.	4.3	48
25	Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes. Diabetes Care, 2012, 35, 2647-2649.	4.3	44
26	A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care, 2018, 41, 1672-1680.	4.3	44
27	Mechanisms of Insulin Resistance After Insulin-Induced Hypoglycemia in Humans: The Role of Lipolysis. Diabetes, 2010, 59, 1349-1357.	0.3	43
28	Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes. Diabetes Care, 2008, 31, S113-S120.	4.3	42
29	Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 μ U/mL in People with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 252-257.	2.4	42
30	Gender Differences in Basal Protein Kinetics in Young Adults. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4363-4367.	1.8	41
31	Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes. Diabetes Care, 2015, 38, 503-512.	4.3	41
32	Fluctuation of Serum Basal Insulin Levels Following Single and Multiple Dosing of Insulin Glargine. Diabetes Technology and Therapeutics, 2006, 8, 237-243.	2.4	40
33	The Effect of Asymptomatic Nocturnal Hypoglycemia on Glycemic Control in Diabetes Mellitus. New England Journal of Medicine, 1988, 319, 1233-1239.	13.9	34
34	Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 μ U/mL versus glargine 100 μ U/mL in people with type 1 diabetes (EDITION 4). Diabetes, Obesity and Metabolism, 2018, 20, 121-128.	2.2	34
35	C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective. Diabetes, Obesity and Metabolism, 2022, 24, 1912-1926.	2.2	34
36	The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diabetes Research and Clinical Practice, 1989, 6, S3-S16.	1.1	33

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 85-92.	4.3	32
38	Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, S-43-S-52.	2.4	28
39	Moderate and Large Doses of Ethanol Differentially Affect Hepatic Protein Metabolism in Humans. <i>Journal of Nutrition</i> , 1998, 128, 198-203.	1.3	26
40	Different Brain Responses to Hypoglycemia Induced by Equipotent Doses of the Long-Acting Insulin Analog Detemir and Human Regular Insulin in Humans. <i>Diabetes</i> , 2008, 57, 746-756.	0.3	26
41	Glargine metabolism over 24h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose-response study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 709-716.	1.1	26
42	Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1369-1377.	2.2	26
43	Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology. <i>Current Diabetes Reports</i> , 2018, 18, 83.	1.7	24
44	Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised) <i>Tj ETQq0 0 0 rBT /Overlock 10 Tf 5</i>	1.1	22
45	Insulin Treatment in Type 1 Diabetes. <i>Endocrine Practice</i> , 2006, 12, 105-109.	1.1	22
46	Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1880-1885.	2.2	21
47	New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice. <i>Diabetes Care</i> , 2015, 38, 541-543.	4.3	21
48	Treatment and prevention of hypoglycemia and its unawareness in type 1 diabetes mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2003, 4, 335-341.	2.6	19
49	How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins. <i>Diabetes Care</i> , 2015, 38, 2237-2240.	4.3	18
50	GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. <i>Diabetes and Metabolism</i> , 2015, 41, 6S16-6S20.	1.4	17
51	Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 321-329.	2.2	15
52	Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH. <i>Medicine (United States)</i> , 2017, 96, e6022.	0.4	13
53	Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 315-323.	2.2	13
54	Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S220-S224.	4.3	11

#	ARTICLE	IF	CITATIONS
55	Comparable efficacy with similarly low risk of hypoglycaemia in patientâ€vs physicianâ€managed basal insulin initiation and titration in insulinâ€naïve type 2 diabetic subjects: The Italian Titration Approach Study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3304.	1.7	11
56	Equipotency of insulin glargine 300 and 100 <sc>U/mL</sc> with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs. Diabetes, Obesity and Metabolism, 2021, 23, 166-174.	2.2	10
57	Rational use of insulin analogues in the treatment of type 1 diabetes mellitus. Pediatric Endocrinology Reviews, 2003, 1, 9-21.	1.2	10
58	Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treatâ€toâ€target trials with insulin glargine 100â€%U/<sc>mL</sc> added to oral antidiabetes agents in type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1546-1554.	2.2	8
59	Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2020, 22, 57-61.	2.4	8
60	Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin. Diabetes Care, 2020, 43, 2333-2335.	4.3	8
61	The physiological basis of insulin therapy in people with diabetes mellitus. Diabetes Research and Clinical Practice, 2021, 175, 108839.	1.1	8
62	Insulin Centennial: Milestones influencing the development of insulin preparations since 1922. Diabetes, Obesity and Metabolism, 2022, 24, 27-42.	2.2	8
63	Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes. Postgraduate Medicine, 2019, 131, 117-128.	0.9	7
64	Glycaemic control and hypoglycaemia risk with insulin glargine 300â€%U/mL and insulin degludec 100â€%U/mL in older participants in the BRIGHT trial. Diabetes, Obesity and Metabolism, 2021, 23, 1588-1593.	2.2	7
65	One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs. Metabolism: Clinical and Experimental, 2022, 126, 154935.	1.5	7
66	A <i>postâ€hoc</i> pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Glaâ€300) versus 100 U/mL (Glaâ€100) over wider nocturnal windows in individuals with type 2 diabetes on a basalâ€only insulin regimen. Diabetes, Obesity and Metabolism, 2019, 21, 402-407.	2.2	6
67	Hypoglycaemia risk with insulin glargine 300â€%U/<sc>mL</sc> compared with glargine 100â€%U/<sc>mL</sc> across different baseline fasting Câ€peptide levels in insulinâ€naïve people with type 2 diabetes: A post hoc analysis of the <sc>EDITION</sc> 3 trial. Diabetes, Obesity and Metabolism, 2020, 22, 1664-1669.	2.2	5
68	Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. Diabetes and Metabolism, 2018, 44, 368-372.	1.4	4
69	Clinical strategies for controlling peaks and valleys: type 1 diabetes. International Journal of Clinical Practice, Supplement, 2002, , 65-74.	0.3	4
70	Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulinâ€naïve individuals with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 2894-2898.	2.2	3
71	Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300â€%U/mL versus insulin glargine 100â€%U/mL in Japanese adults with type 2 diabetes: A 12â€month comparison by concomitant sulphonylurea and/or glinide use. Diabetes, Obesity and Metabolism, 2018, 20, 2541-2550.	2.2	3
72	Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128â€2136. Diabetes Care, 2021, 44, e59-e60.	4.3	3

#	ARTICLE	IF	CITATIONS
73	Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin. <i>Diabetes Care</i> , 2015, 38, e96-e97.	4.3	2
74	Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an <sc>ITAS</sc> post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 327-331.	2.2	2
75	Long-Term Intervention Studies Using Insulin in Patients with Type 1 Diabetes. <i>Endocrine Practice</i> , 2006, 12, 80-84.	1.1	2
76	Reply to DeVries. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 129-129.	2.4	1
77	John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes. <i>Diabetes Care</i> , 2018, 41, 2059-2063.	4.3	1
78	Real-time continuous glucose monitoring decreases the risk of severe hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia. <i>Annals of Translational Medicine</i> , 2018, 6, S97-S97.	0.7	1
79	1088-P: A PK/PD and Metabolic Head-to-Head Comparison of Clinical Doses of Insulin Glargine U300 and Degludec in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1088-P.	0.3	1
80	Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia. <i>Postgraduate Medicine</i> , 2004, 116, 13-20.	0.9	1
81	Come prevenire e trattare lâ€™ipoglicemia e la sindrome dellâ€™ipoglycaemia unawarenessâ€™ nel diabete mellito di tipo 1. <i>L Endocrinologo</i> , 2003, 4, 187-197.	0.0	0
82	Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS. <i>Acta Diabetologica</i> , 2021, 58, 789-796.	1.2	0